Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.49 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | KDM1A | O60341 | 1/20 | 0.48 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.46 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4930924 | 0.89 | CYP2C9 (0.50) | GPR119CYP2C9KDM1AUSP30 | |
| SCHEMBL12205335 | 0.88 | KDM4E (0.55) | GPR119CYP2D6CYP2C9GRIN2BKDM4E | |
| SCHEMBL6148442 | 0.86 | CYP2D6 (0.64) | GPR119CYP2D6CYP2C9GRIN2BKDM4E | |
| SCHEMBL4929565 | 0.85 | ALDH1A1 (0.56) | GPR119PTPN2PTPN1PTPN6USP30 | |
| SCHEMBL12247504 | 0.84 | KDM4E (0.51) | GPR119CYP2D6CYP2C9GRIN2BKDM4E | |
| SCHEMBL4933041 | 0.84 | GRIN2B (0.50) | CYP2D6CYP2C9GRIN2BCYP3A4USP30 | |
| SCHEMBL15206132 | 0.83 | IDO1 (0.53) | GPR119CYP2D6CYP2C9GRIN2BKDM4E | |
| SCHEMBL12205201 | 0.81 | TGFBR1 (0.56) | GPR119KDM4EPKMTGFBR1 | |
| SCHEMBL13690395 | 0.79 | GPR119 (0.56) | GPR119CYP2D6CYP2C9GRIN2BKDM4E | |
| SCHEMBL4930989 | 0.78 | MKNK1 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080194584-A1 | Nitrogen Heteroaromatic Compounds Which Bind To The Active Site Of Protein Kinase Enzymes | GALAPAGOS NV (BE) | 2008-08-14 | — | — | US | claimed |
| US-20080194584-A1 | Nitrogen Heteroaromatic Compounds Which Bind To The Active Site Of Protein Kinase Enzymes | GALAPAGOS NV (BE) | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194584-A1 | Nitrogen Heteroaromatic Compounds Which Bind To The Active Site Of Protein Kinase Enzymes | ROCK1, TNK2, GRK1 | GPR119 316/4885CYP2D6 2175/4885CYP2C9 1971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.